CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
Axitinib (AG-013736)drug
Likely dose
Axitinib (AG-013736) 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00447005
NCT00447005Phase 1Completed
CompareCT.gov

A Phase 1 Study Of AG-013736 (Axitinib) In Japanese Patients With Advanced Solid Tumors

Pfizer·interventional·Posted Mar 13, 2007·Updated May 23, 2012

In Brief

A Phase 1 clinical trial evaluating Axitinib (AG-013736) for Carcinoma. Completed, enrolled 12 participants across 1 site.

Detailed Summary

To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2007
Enrollment StartFeb 1, 2007
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.3 years ago

Interventions

Axitinib (AG-013736)drug

AG-013736 5mg twice daily \[BID\]